KR101247927B1 - Composition for prevention or relief of alcoholic hangover - Google Patents
Composition for prevention or relief of alcoholic hangover Download PDFInfo
- Publication number
- KR101247927B1 KR101247927B1 KR1020120077421A KR20120077421A KR101247927B1 KR 101247927 B1 KR101247927 B1 KR 101247927B1 KR 1020120077421 A KR1020120077421 A KR 1020120077421A KR 20120077421 A KR20120077421 A KR 20120077421A KR 101247927 B1 KR101247927 B1 KR 101247927B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- embryo
- composition
- saccharomyces
- lotus root
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 230000002265 prevention Effects 0.000 title claims description 7
- 206010001623 Alcoholic hangover Diseases 0.000 title abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 156
- 238000000855 fermentation Methods 0.000 claims abstract description 93
- 230000004151 fermentation Effects 0.000 claims abstract description 93
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 65
- 241000196324 Embryophyta Species 0.000 claims abstract description 51
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 42
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 28
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 27
- 240000000249 Morus alba Species 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 25
- 244000005700 microbiome Species 0.000 claims abstract description 19
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 18
- 240000007594 Oryza sativa Species 0.000 claims abstract description 16
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 16
- 235000009566 rice Nutrition 0.000 claims abstract description 16
- 241000235070 Saccharomyces Species 0.000 claims abstract description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 12
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims abstract description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 241000235644 Issatchenkia Species 0.000 claims abstract description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 7
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 6
- 241000938061 Streptomyces thermophilus Species 0.000 claims abstract description 5
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 3
- 235000009165 saligot Nutrition 0.000 claims abstract 7
- 240000001085 Trapa natans Species 0.000 claims abstract 3
- 206010019133 Hangover Diseases 0.000 claims description 29
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 28
- 240000006891 Artemisia vulgaris Species 0.000 claims description 28
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- 235000021374 legumes Nutrition 0.000 claims description 7
- 229940081969 saccharomyces cerevisiae Drugs 0.000 claims description 7
- 239000002131 composite material Substances 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 229960004793 sucrose Drugs 0.000 claims description 5
- 241000186660 Lactobacillus Species 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 235000013681 dietary sucrose Nutrition 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 241000235072 Saccharomyces bayanus Species 0.000 claims description 2
- 241000187747 Streptomyces Species 0.000 claims description 2
- 244000078912 Trichosanthes cucumerina Species 0.000 claims 3
- 235000010804 Maranta arundinacea Nutrition 0.000 claims 1
- 235000003283 Pachira macrocarpa Nutrition 0.000 claims 1
- 244000145580 Thalia geniculata Species 0.000 claims 1
- 235000012419 Thalia geniculata Nutrition 0.000 claims 1
- 235000014364 Trapa natans Nutrition 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 abstract description 54
- 244000302512 Momordica charantia Species 0.000 abstract description 15
- 238000000354 decomposition reaction Methods 0.000 abstract description 4
- 235000009812 Momordica cochinchinensis Nutrition 0.000 abstract description 3
- 235000018365 Momordica dioica Nutrition 0.000 abstract description 3
- 241000235645 Pichia kudriavzevii Species 0.000 abstract description 2
- 241000531873 Pichia occidentalis Species 0.000 abstract description 2
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 abstract 4
- 241000159213 Zygophyllaceae Species 0.000 abstract 4
- 235000008658 Artemisia capillaris Nutrition 0.000 abstract 2
- 241000092668 Artemisia capillaris Species 0.000 abstract 2
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 2
- 244000046146 Pueraria lobata Species 0.000 abstract 2
- 239000013065 commercial product Substances 0.000 abstract 1
- 229940093499 ethyl acetate Drugs 0.000 abstract 1
- 235000019439 ethyl acetate Nutrition 0.000 abstract 1
- 239000000126 substance Substances 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 18
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 239000000843 powder Substances 0.000 description 12
- 238000001914 filtration Methods 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 150000001720 carbohydrates Chemical class 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 10
- 239000013642 negative control Substances 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 235000013399 edible fruits Nutrition 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 239000008176 lyophilized powder Substances 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000000593 degrading effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 235000001727 glucose Nutrition 0.000 description 5
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 4
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 241000588722 Escherichia Species 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 3
- 235000003097 Artemisia absinthium Nutrition 0.000 description 3
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 3
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 239000002518 antifoaming agent Substances 0.000 description 3
- 239000001138 artemisia absinthium Substances 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 235000002949 phytic acid Nutrition 0.000 description 3
- 239000000467 phytic acid Substances 0.000 description 3
- 229940068041 phytic acid Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- -1 sucrose polysaccharides Chemical class 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- 244000008991 Curcuma longa Species 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 108010033145 microsomal ethanol-oxidizing system Proteins 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 108010075550 termamyl Proteins 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 240000007108 Fuchsia magellanica Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 102100034866 Kallikrein-6 Human genes 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241001126925 Lobata Species 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000009815 Momordica Nutrition 0.000 description 1
- 241000218984 Momordica Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241000218213 Morus <angiosperm> Species 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000005807 Nelumbo Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 240000001439 Opuntia Species 0.000 description 1
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 241000218206 Ranunculus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241001083492 Trapa Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 244000195452 Wasabia japonica Species 0.000 description 1
- 235000000760 Wasabia japonica Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229930010796 primary metabolite Natural products 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960002181 saccharomyces boulardii Drugs 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 숙취 예방 또는 해소용 조성물에 관한 것이다.The present invention relates to a composition for preventing or eliminating hangovers.
알코올은 현대인의 스트레스 해소를 위해 소비가 급증하고 있는 추세에 있다. 하지만, 다량의 알코올을 섭취하면서 알코올성 숙취로 인한 메스꺼움, 구토, 현기증, 갈증, 무기력, 두통, 근육통 등의 증상이 야기되고 이는 업무 능률 저하로 인한 사회 경제적 손해를 초래하고 있다(Swift R, Davidson D, Alcohol hangover: mechanisms and mediators. Alcohol Health Res World, 22(1):54-60, 1998).Alcohol is on the rise in consumption to relieve stress of modern people. However, drinking large amounts of alcohol causes symptoms such as nausea, vomiting, dizziness, thirst, lethargy, headache, and muscle aches from alcoholic hangovers, resulting in socioeconomic damages due to poor work efficiency (Swift R, Davidson D). Alcohol hangover: mechanisms and mediators.Alcohol Health Res World, 22 (1): 54-60, 1998).
알코올은 체내에 흡수될 경우 3가지 경로로 통해 대사되는데, 알코올 농도가 낮을 때는 위장관 또는 간에 존재하는 ADH(alcohol dehydrogenase)와 ALDH(acetaldehyde dehydrogenase)의 작용에 의해, 알코올 농도가 높을 때는 소포체에 존재하는 마이크로좀 에탄올 산화체계(MEOS: Microsomal ethanol oxidizing system)에 의해 아세트알데하이드와 아세트산으로 대사되며, 이후 퍼옥시좀(peroxisome)에 존재하는 카탈라제(catalase)의 작용 등을 거쳐 이산화탄소와 물로 최종 분해된다(한국공개특허 제10-2012-0016688호, 2012년 2월 27일, [0005] 단락).Alcohol is metabolized through three pathways when absorbed into the body.At low alcohol levels, alcohol is present in the endoplasmic reticulum by the action of ADH (alcohol dehydrogenase) and ALDH (acetaldehyde dehydrogenase) in the gastrointestinal tract or liver. It is metabolized to acetaldehyde and acetic acid by the microsomal ethanol oxidizing system (MEOS), and then finally decomposed into carbon dioxide and water through the action of catalase present in the peroxisome (Korea) Korean Patent Publication No. 10-2012-0016688, February 27, 2012, paragraph [0005].
적당량의 알코올이 유입되면 상기 대사체계가 원활하게 작용하여 알코올 때문에 일어나는 제반 증상이 일어나지 않지만, 다량의 알코올 유입 시 대사체계의 균형이 파괴되어 생체 항상성을 유지하지 못하게 된다. 알코올이 산화되어 만들어진 일차 대사산물인 아세트알데하이드는 숙취의 주요한 인자이며, 알코올 섭취 시 체내의 독성작용을 통해 알코올 그 자체보다 아세트알데하이드에 의한 숙취의 영향이 더 크다. 체내에서 생성된 아세트알데하이드는 뇌로 전해져 많은 유해화합물로 바뀌어 맥박 증가나 발한, 홍조, 오심, 구토 등의 증상을 초래할 수 있다(한국공개특허 제10-2012-0016688호, 2012년 2월 27일, [0006] 단락).When the proper amount of alcohol is introduced, the metabolic system works smoothly and does not cause any symptoms caused by alcohol, but when the large amount of alcohol is introduced, the balance of the metabolic system is destroyed and thus the homeostasis cannot be maintained. Acetaldehyde, a primary metabolite made by oxidizing alcohol, is a major factor in hangover, and the effects of hangover by acetaldehyde are greater than alcohol itself through alcohol toxicity. Acetaldehyde produced in the body is transmitted to the brain and converted into many harmful compounds, which can cause symptoms such as increased pulse, sweating, flushing, nausea, and vomiting (Korea Patent Publication No. 10-2012-0016688, Feb. 27, 2012, Paragraph [0006].
따라서 알코올성 숙취를 단시간에 효과적으로 해소하기 위해서는 체내 알코올 농도의 감소와 함께 아세트알데하이드의 농도의 감소를 효과적으로 시킬 수 있는 알코올 분해능력 및 아세트알데하이드 분해능력이 우수한 조성물의 개발이 요구되고 있다. 이는 알코올 분해능력이 우수하나 아세트알데하이드 분해능력이 우수하지 않은 조성물의 경우 체내에 아세트알데하이드가 축적되어 숙취해소에 효과적이지 않을 수 있고, 알코올 분해능력이 우수하지 않으나 아세트알데하이드 분해능력이 우수한 조성물의 경우 체내 알코올이 모두 분해되는데 장시간이 소요되므로 체내 아세트알데하이드 농도가 낮은 수치라도 오랜 시간 노출될 수 있어 효과적이지 않을 수 있기 때문이다.Therefore, in order to effectively solve the alcoholic hangover in a short time, it is required to develop a composition having excellent alcohol decomposing ability and acetaldehyde decomposing ability which can effectively decrease the concentration of acetaldehyde with the decrease of the alcohol concentration in the body. This is a composition that has good alcohol decomposing ability but not acetaldehyde decomposing ability, and may be ineffective in relieving hangover due to accumulation of acetaldehyde in the body, and in the case of a composition which does not have good alcohol decomposing ability but excellent acetaldehyde decomposing ability. Because it takes a long time to decompose all the alcohol in the body, even low levels of acetaldehyde in the body may be exposed for a long time may not be effective.
이에 본 발명자들은 알코올 분해능력 및 아세트알데하이드 분해능력이 우수하여 숙취 예방 또는 해소에 효과적인 조성물을 찾고자 노력한 결과 (a) 마름 추출물, (b) 인진쑥, 녹엽, 뽕잎, 여주, 칡 및 연근의 식물발효추출물 및 (c) 미배아 복합발효추출액을 포함하는 조성물이 알코올 분해능력 및 아세트알데하이드 분해능력이 우수함을 발견하고 본 발명을 완성하였다.Accordingly, the present inventors have tried to find a composition that is effective in preventing or eliminating hangovers because of excellent alcohol decomposing ability and acetaldehyde decomposing ability, and thus (a) dried extract, (b) plant fermentation extracts of jinjin wormwood, green leaf, mulberry leaf, bitter gourd, 칡 and lotus root. And (c) found that the composition containing the embryo embryo complex fermentation extract has excellent alcohol decomposing ability and acetaldehyde decomposing ability and completed the present invention.
따라서 본 발명의 목적은 알코올 분해능력 및 아세트알데하이드 분해능력이 우수하여 숙취 예방 또는 해소에 효과적인 조성물을 제공하는 데에 있다.Accordingly, an object of the present invention is to provide a composition effective in preventing or eliminating hangover due to excellent alcohol decomposing ability and acetaldehyde decomposing ability.
상기 목적을 달성하기 위하여, 본 발명은 (a) 마름 추출물, (b) 인진쑥, 녹엽, 뽕잎, 여주, 칡 및 연근의 식물발효추출물 및 (c) 미배아 복합발효추출액을 포함하는 숙취 예방 또는 해소용 조성물을 제공한다.In order to achieve the above object, the present invention (a) dried extract, (b) jinjin mugwort, green leaf, mulberry leaf, Yeoju, 칡 and lotus root plant fermentation extract and (c) embryo embryo complex fermentation extract preventing or eliminating It provides a composition for.
마름은 마름과(Hydrocaryaceae)에 속하는 Trapa japonica Flerov 또는 기타 동속 근연식물이다. 마름은 1년생 초본으로 물속에서 자란다. 마름열매인 능실은 약 15%가 전분으로 구성되어 있으며, 이외에도 포도당, 단백질, 비타민 C, 비타민 B 등의 성분을 함유하고 약간 단맛을 가지고 있다.Dermis is Trapa , belonging to the Hydrocaryaceae family japonica Flerov or other cognate plant. Marm is an annual herb that grows in water. About 15% of the walnut fruit, which is a rhombus, is composed of starch. In addition, it contains glucose, protein, vitamin C, and vitamin B, and has a slightly sweet taste.
본 발명에서 마름은 자연상태, 반건조, 건조 등의 가공된 마름도 본 발명의 범위에 포함된다. 또한 본 발명에서 마름은 마름 전체 또는 일부, 예컨대 마름의 잎, 줄기, 뿌리, 열매, 종자 등이 사용될 수 있으며, 바람직하게는 마름의 잎이 이용될 수 있다.In the present invention, dried is also included in the scope of the present invention processed natural dry, such as semi-dry, drying. Also, in the present invention, the whole or part of the dried leaves may be used, for example, leaves, stems, roots, fruits, seeds, etc. of the dried leaves, and preferably dried leaves may be used.
본 발명에서 (a) 마름 추출물은 마름 자체를 그대로 또는 세절 또는 분말 형태로 하여, 통상적인 추출 방법, 예를 들면 열수 추출 또는 유기용매로 추출하여 제조할 수 있다. 또한 본 발명의 마름 추출물은 상기 추출물을 건조시켜 얻어진 건조분말 또는 시판되는 (a) 마름 추출물 분말일 수도 있다. 추출물 제조 시에 마름은 건조한 것, 건조하지 않은 것 또는 이들을 서로 혼합한 상태의 것을 사용할 수 있다. (a) 마름 추출물은, 예를 들어, 건조시킨 생약을 세절한 후, 약 3배 내지 1000배 중량의 물, 유기용매 또는 이들의 혼합용매로 실온 내지 60~130℃의 추출온도에서 약 1시간 내지 10일 동안 열수추출, 냉침추출, 초고압 추출 또는 환류냉각 추출 등의 추출방법에 의하여 1회 내지 5회 반복하여 추출한 후, 추출물을 여과, 감압농축 또는 동결건조하여 제조될 수 있다. 상기 유기용매로는 탄소수 1 내지 4의 알코올, 에틸아세테이트, 클로로포름, 헥산, 디클로로메탄 등을 예시할 수 있다.In the present invention (a) the dry extract may be prepared by extracting the extract itself with a conventional extraction method, for example, hot water extraction or an organic solvent, as it is or in the form of finely divided or powdered. In addition, the dried extract of the present invention may be a dry powder obtained by drying the extract or commercially available (a) dried extract powder. In the preparation of the extract, dried, undried, or a mixture of them can be used. (a) The dried extract is, for example, after cutting the dried herbal medicine, about 3 hours to 1000 times the weight of water, organic solvent or a mixed solvent thereof at room temperature to 60 ~ 130 ℃ extraction temperature for about 1 hour After extracting repeatedly from 1 to 5 times by an extraction method such as hot water extraction, cold sediment extraction, ultra-high pressure extraction or reflux cooling extraction for from 10 days, the extract may be prepared by filtration, concentrated under reduced pressure or lyophilized. Examples of the organic solvent include alcohols having 1 to 4 carbon atoms, ethyl acetate, chloroform, hexane, dichloromethane, and the like.
본 발명에서 (a) 마름 추출물은 물, 탄소수 1 내지 4의 알코올, 에틸아세테이트, 클로로포름, 헥산, 디클로로메탄 또는 이들의 혼합용매로 추출된 것일 수 있다.In the present invention (a) the dry extract may be extracted with water, alcohol having 1 to 4 carbon atoms, ethyl acetate, chloroform, hexane, dichloromethane or a mixed solvent thereof.
본 발명에서 (b) 인진쑥, 녹엽, 뽕잎, 여주, 칡 및 연근의 식물발효추출물(이하 식물발효추출물)은 인진쑥, 녹엽, 뽕잎, 여주, 칡 및 연근을 스트렙토마이세스 써모필러스(Streptomycesthermophilus),락토바실러스 에시도필러스(Lactobacillusacidophilus),사카로마이세스 세레비지애(Saccharomycescerevisiae),바실러스 섭틸리스(Bacillussubtilis)를 1:1:1:1의 중량비로 혼합한 혼합종균에 의해 발효시켜서 얻어진 발효추출물이다.In the present invention (b) the plant fermentation extracts of jinjin mugwort, green leaves, mulberry leaves, bitter gourd, 칡 and lotus root (hereinafter referred to as plant fermentation extract) is Streptomyc thermophilus ( Streptomycesthermophilu s) , Lactobacillus Ecija FIG filler's (Lactobacillusacidophilus), saccharose in my process three Levy jiae (Saccharomycescerevisiae), B. subtilis (Bacillussubtilis) a 1: 1: 1: 1 into effect obtained by fermentation by a mixture of microorganisms mixed in a weight ratio of Extract.
인진쑥은 국화과(Asteraceae)에 속하는 Artemisia capillaris 또는기타동속근연식물이다. 사철쑥 또는 더위지기라고도 불리며 생약명은 인진호(茵蔯蒿)이다. 인진쑥은 사절봉, 조선인진호, 사인호, 인진, 백호, 가인진, 석인진, 인진고, 댕강쑥 등으로 불리기도 한다. 인진쑥은 고대 중국 후한시대에 화타(華陀)라는 명의에 의해 발견된 이후 한방에서 생약재로 이용하게 되었다. 다년생 초본으로 초장은 30∼100 ㎝ 정도이며, 우상(羽狀)으로 완전히 갈라지며, 8∼9월 사이에 황색꽃이 피고 10월경에 성숙한다. 어린 순과 잎은 예로부터 쑥떡, 쑥차로 이용되어 왔다.Inemisia Artemisia belongs to the Asteraceae capillaris Or other homologous plants. It is also called wormwood or heat keeper, and the herbal name is Injin Ho. Injin mugwort is also called Sajeolbong, Chosun Injinho, Sineho, Injin, Whiteho, Gainjin, Seokjinjin, Injingo, and Danggangmugwort. Injin mugwort was discovered in ancient China by the name of Hua Ta, and used as a herbal medicine in oriental medicine. It is a perennial herb, 30-100 cm long, completely divided into idols, and yellow flowers bloom between August and September and mature around October. Young sprouts and leaves have been used as mugwort rice cakes and mugwort teas since ancient times.
본 발명에서 인진쑥은 자연상태, 반건조, 건조 등의 가공된 인진쑥도 본 발명의 범위에 포함된다. 예를 들어, 본 발명에서 인진쑥은 동결건조된 분말형태를 이용할 수 있다. 또한 본 발명에서 인진쑥은 인진쑥 전체 또는 일부, 바람직하게는 인진쑥의 전초가 이용될 수 있다.Injin mugwort in the present invention is a natural state, semi-dried, dried and processed injin mugwort is also included in the scope of the present invention. For example, in the present invention, the jinjin mugwort may use a lyophilized powder form. In the present invention, the jinjin mugwort may be used in whole or in part of the jinjin mugwort, preferably jinjin mugwort.
본 발명에서 녹엽은 차나무과(Theaceae)에 속하는 Thea sinensis L. 또는기타동속근연식물의잎이다. 녹엽은 통상 녹차잎이라고도 불린다. 녹엽은 국내외에서 널리 사용되고 있는 식품소재로서 주로 차의 형태로 섭취되어 왔다.In the present invention is nokyeop Thea belonging to theaceae (Theaceae) sinensis L. or other homogenous root plant. Green leaves are also commonly called green tea leaves. Green leaf is a food material widely used at home and abroad and has been ingested mainly in the form of tea.
녹차의 물 또는 주정 추출물은 현재 식품의 원료로 사용되고 있으며, 산화방지제의 용도, 독소제거효능, 혈관질환 예방 효능, 암 예방 효능 등이 있는 것으로 알려져 있다.Water or alcohol extract of green tea is currently used as a raw material of food, it is known that the use of antioxidants, toxin removal effect, vascular disease prevention effect, cancer prevention effect and the like.
본 발명에서 녹엽은 자연상태, 반건조, 건조 등의 가공된 녹엽도 본 발명의 범위에 포함된다. 예를 들어, 본 발명에서 녹엽은 동결건조된 분말형태를 이용할 수 있다.In the present invention, the green leaf is processed in the natural state, semi-dried, dried green leaves also fall within the scope of the present invention. For example, the green leaves in the present invention may use a lyophilized powder form.
뽕잎은 뽕나무과(Moraceae)에 속하는 Morus alba Linne 또는 기타 동속 근연식물의 잎이다.Mulberry is Morus belonging to Moraceae alba Linne or other related plant leaves.
본 발명에서 뽕잎은 자연상태, 반건조, 건조 등의 가공된 뽕잎도 본 발명의 범위에 포함된다. 예를 들어, 본 발명에서 뽕잎은 동결건조된 분말형태를 이용할 수 있다.In the present invention, the mulberry leaves in the natural state, semi-dried, dried and processed mulberry leaves are also included in the scope of the present invention. For example, in the present invention, the mulberry leaf may use a lyophilized powder form.
여주는 박과(Cucurbitaceae)에 속하는 Momordica charantia Linn 또는 기타 동속 근연식물이다. 여주는 원산지가 아시아 열대지방이며 덩굴성 한해살이 풀이며, 통상적으로는 bitter melon, balsam pear로 불린다. 줄기는 가늘고 길이 3∼7m로 자라며 더 크게 자랄 수도 있다. 잎은 어긋나고 잎자루가 길며, 열매는 긴 타원형이고 양끝이 좁으며 혹 같은 돌기가 있고 처음엔 녹색이나 익어감에 따라 연두색, 연녹색, 황적색으로 익으면 불규칙하게 갈라져서 선홍색 육질로 싸인 종자가 나온다. 여주는 우리나라의 전역에서 자연적으로 자라며, 또는 재배되기도 한다.The hostess is Momordica belonging to the family Cucurbitaceae . charantia Linn or other cognate plant. Yeoju is native to tropical Asia and is a vine annual herb. It is commonly called bitter melon or balsam pear. Stems are thin, grow to 3-7m long, and may grow larger. The leaves are alternate, the petioles are long, the fruits are long oval, the both ends are narrow, hump-like projections, and when the green or ripening ripens to yellow-green, light green, yellow-red, the seeds are irregularly divided and wrapped in a crimson flesh. Yeoju grows or grows naturally throughout Korea.
본 발명에서 여주는 자연상태, 반건조, 건조 등의 가공된 여주도 본 발명의 범위에 포함된다. 예를 들어, 본 발명에서 여주는 동결건조된 분말형태를 이용할 수 있다. 또한 본 발명에서 여주는 여주 전체 또는 일부, 예컨대 여주의 잎, 줄기, 뿌리, 열매, 종자 등이 사용될 수 있으며, 바람직하게는 여주의 열매가 이용될 수 있다.In the present invention, the processed bitter gourd, such as natural state, semi-dry and dried, is also included in the scope of the present invention. For example, the litchi in the present invention may use a lyophilized powder form. In addition, in the present invention, all or part of the bitter gourd, such as leaves, stems, roots, fruits, seeds, etc. of the bitter gourd may be used, and preferably the fruit of the bitter gourd may be used.
칡은 콩과(Fabaceae/Leguminosae)에 속하는 Pueraria lobata Ohwi 또는 기타 동속 근연식물이다. 칡은 우리나라 각처의 산기슭 양지에 나는 낙엽 덩굴나무이다. 잎은 3장의 작은 잎으로 된 겹잎으로 이루어져 있고 작은 잎은 넓은 난형이고 가장자리가 밋밋하거나 얕게 2-3갈래이며, 꽃은 총상화서이고 잎겨드랑이에 붙으며 자홍색이고, 열매는 협과, 선형, 갈색의 강모가 밀생으로 길이 4-9cm이다. 개화기는 8월이고 결실기 9-10월이다. Pueraria belonging to the family Legume ( Fabaceae / Leguminosae ) lobata Ohwi or other cognate plant. 칡 is a deciduous vine that grows in the foothills of Korea. The leaf is composed of 3 leaflets of double leaf, the small leaves are broad ovate, flat or shallow at 2-3 edges, the flowers are genus inflorescences, attached to the axillas and fuchsia, and the fruits are nectar, linear, and brown. Bristles are dense, 4-9 cm long. Blooming season is August and fruiting season is September-October.
본 발명에서 칡은 자연상태, 반건조, 건조 등의 가공된 칡도 본 발명의 범위에 포함된다. 예를 들어, 본 발명에서 칡은 동결건조된 분말형태를 이용할 수 있다. 또한 본 발명에서 칡은 칡 전체 또는 일부, 예컨대 칡의 잎, 줄기, 뿌리, 열매, 종자 등이 사용될 수 있으며, 바람직하게는 칡의 뿌리가 이용될 수 있다.In the present invention, 칡 is processed in the natural state, semi-drying, drying and the like is also included in the scope of the present invention. For example, in the present invention, thin lyophilized powder may be used. In addition, in the present invention, 칡 may be used in whole or in part, such as leaves, stems, roots, fruits, seeds, etc. of the 칡, preferably the root of 칡 may be used.
연근은 연꽃과(Nelumboaceae)에 속하는 Nelumbo nucifera Gaertn 또는 기타 동속 근연식물의 뿌리줄기이다.Lotus root is Nelumbo belonging to the family Nelumboaceae nucifera Root stem of Gaertn or other cohort of related plants.
본 발명에서 연근은 자연상태, 반건조, 건조 등의 가공된 연근도 본 발명의 범위에 포함된다. 예를 들어, 본 발명에서 연근은 동결건조된 분말형태를 이용할 수 있다.In the present invention, the lotus root is processed in the natural state, semi-dried, dried, etc. also fall within the scope of the present invention. For example, in the present invention, lotus root may be used as a lyophilized powder.
본 발명에서 (b) 식물발효추출물은 스트렙토마이세스 써모필러스, 락토바실러스 에시도필러스, 사카로마이세스 세레비지애, 바실러스 섭틸리스를 1:1:1:1의 중량비로 혼합한 혼합종균을 준비하는 종균준비단계; 상기 혼합종균 1 중량부와 상기 혼합종균 1 중량부 기준 50 내지 200 중량부의 인진쑥, 50 내지 250 중량부의 녹엽을 혼합하여 용기에 투입하고 용기에 기포기를 이용하여 산소를 공급한 채 2-4개월 동안 상온에서 배양하여 1차 배양액을 제조하는 1차 배양 단계; 상기 혼합종균 1 중량부 기준 50 내지 200 중량부의 인진쑥, 50 내지 200 중량부의 녹엽, 50 내지 200 중량부의 뽕잎, 50 내지 250 중량부의 여주, 50 내지 100 중량부의 칡, 25 내지 75 중량부의 연근을 준비하여 1차 배양액에 혼합하여 동일한 환경에서 1 내지 2개월 동안 상온에서 배양하여 2차 배양액을 제조하는 2차 배양단계; 및 상기 2차 배양액을 상온에서 1 내지 2개월 숙성시키는 숙성단계를 포함하는 공정에 의해 제조될 수 있다.In the present invention (b) plant fermentation extract is a mixture of Streptomyces thermophilus, Lactobacillus ecidophilus, Saccharomyces cerevisiae, Bacillus subtilis in a weight ratio of 1: 1: 1: 1 Spawn preparation step for preparing spawn; 1 to 1 part by weight of the mixed seedlings and 50 to 200 parts by weight of phosphorus mugwort based on 1 part by weight of the mixed seedlings, 50 to 250 parts by weight of green leaves are mixed and put into a container, and the container is supplied with oxygen using a bubbler for 2-4 months. A primary culture step of preparing a primary culture by culturing at room temperature; Prepare 50 to 200 parts by weight of phosphorus mugwort, 50 to 200 parts by weight of green leaves, 50 to 200 parts by weight of mulberry leaves, 50 to 250 parts by weight of bitter gourd, 50 to 100 parts by weight, and 25 to 75 parts by weight of lotus root based on 1 part by weight of the mixed seed. Secondary culture step of preparing a secondary culture solution by mixing in the primary culture solution and incubated at room temperature for 1 to 2 months in the same environment; And it can be prepared by a process comprising a aging step of aging the secondary culture at room temperature for 1 to 2 months.
본 발명에서 상온은 15 내지 25℃를 의미한다.In the present invention, room temperature means 15 to 25 ℃.
상기 공정은 상기 2차 배양액을 여과하고 농축시키는 여과 및 농축 단계를 더 포함할 수 있다.The process may further comprise a filtration and concentration step of filtering and concentrating the secondary culture.
상기 여과는 여과 효율을 증진시키기 위하여 2차 배양액에 물 및 탄수화물 분해효소를 첨가하여 여과하는 것이 바람직하다.The filtration is preferably filtered by adding water and carbohydrate degrading enzyme to the secondary culture in order to enhance the filtration efficiency.
상기 탄수화물 분해효소로는 프로모자임(Promozyme), 셀루클라스트(Celluclast), 말토게나제(Maltogenase), 비스코자임(Viscozyme), 테르마밀(Termamyl), 덱스트로자임(Dextrozyme), 울트라플로(Ultraflo) 및 AMG로 이루어진 군에서 선택된 하나 이상을 사용할 수 있고, 바람직하게는 테르마밀(Termamyl)과 비스코자임(Viscozyme)을 동일 중량 비율로 혼합하여 사용하며, 이때 발효 배양물 총 100 중량부에 대하여 탄수화물 분해효소를 0.001 내지 1 중량부로 포함하는 것이 바람직하다.The carbohydrate degrading enzymes include Promozyme, Cellluclast, Maltogenase, Maltogenase, Biscozyme, Teramyl, Dextrozyme, Ultraflo. And one or more selected from the group consisting of AMG may be used, preferably Teramyl and Biscozyme are mixed in the same weight ratio, wherein the carbohydrate decomposition for a total of 100 parts by weight of the fermentation culture It is preferable to include the enzyme in 0.001 to 1 parts by weight.
본 발명에서 (c) 미배아 복합발효추출액은 미배아, 쌀겨 및 콩류 유래 펩타이드를 사카로마이세스(Saccharomyces)속 및 이사첸키아(Issatchenkia)속 미생물로 이루어진 군에서 선택된 하나 이상의 미생물에 의해 발효시켜서 얻어진 발효추출물이다.In the present invention (c) the embryo embryo complex fermentation extract is fermented by at least one microorganism selected from the group consisting of Saccharomyces ( Saccharomyces ) and Isschenchen genus microorganisms derived from the embryos, rice bran and legumes Fermented extract obtained.
본 발명에서 (c) 미배아 복합발효추출액은 미배아 1 내지 10 중량%, 쌀겨 1 내지 10 중량%, 콩류 유래 펩타이드 0.1 내지 5 중량%, 피틴산 0.1 내지 5 중량%, 이인산나트륨 0.5 내지 5 중량%, 이인산칼륨 0.05 내지 2 중량%, 글루코오스 0.5 내지 5 중량%, 소포제 0.001 내지 0.1 중량% 및 잔부의 물을 사카로마이세스(Saccharomyces)속 및 이사첸키아(Issatchenkia)속 미생물로 이루어진 군에서 선택된 하나 이상의 미생물에 의해 발효시켜서 얻어질 수 있다.In the present invention (c) the embryo complex composite fermentation extract is 1-10% by weight of embryos, 1-10% by weight of rice bran, 0.1-5% by weight of peptides derived from legumes, 0.1-5% by weight of phytic acid, 0.5-5% by weight of sodium diphosphate %, Potassium diphosphate 0.05 to 2% by weight, glucose 0.5 to 5% by weight, antifoaming agent 0.001 to 0.1% by weight and the balance of water in the group of Saccharomyces genus and Issatchenkia genus It can be obtained by fermentation by one or more microorganisms selected.
상기 쌀겨는 탈지쌀겨일 수 있고, 상기 콩류 유래 펩타이드는 대두 펩타이드일 수 있다.The rice bran may be skim rice bran, the legume-derived peptide may be a soybean peptide.
사카로마이세스속 미생물은 사카로마이세스 세레비지애(Saccharomycescerevisiae), 사카로마이세스 보울라디(SaccharomycesBoulardii),사카로마이세스 바야누스(Saccharomycesbayanus) 등이 포함되며, 바람직하게는 사카로마이세스 세레비지애일 수 있다.Saccharide in my process in the microorganism Saccharomyces as MY process three Levy jiae (Saccharomycescerevisiae), saccharose in my process bowl radio (SaccharomycesBoulardii), saccharose in my process bar Janus (Saccharomycesbayanus) and the like, preferably a saccharide as MY process three It can be Leviathan.
이사첸키아(Issatchenkia)속 미생물은 이사첸키아 오리엔탈리스 (Issatchenkiaorientalis),이사첸키아 옥시덴탈리스(Issatchenkiaoccidentalis)등이 포함되며, 바람직하게는 이사첸키아 오리엔탈리스 MFST1(IssatchenkiaorientalisMFST1)일 수 있다.Moving may be Escherichia Chen (Issatchenkia) in the microorganism Escherichia director Chen Oriental less (Issatchenkiaorientalis), director Chen Escherichia Occidental less (Issatchenkiaoccidentalis) is incorporated and the like, preferably moving Chen Escherichia Oriental less MFST1 (IssatchenkiaorientalisMFST1).
상기 사카로마이세스(Saccharomyces)속 미생물은 크림 황갈색, 이사첸키아(Issatchenkia)속 미생물은 크림 백색을 띠고 있다. 두 가지 미생물 모두 유포자효모의 일종으로 출아에 의한 번식을 하며 열에 강하여 발효과정 중 특정온도 이상에서 발효 시에 우점하여 다른 잡균의 번식을 억제하는 특성이 있어서 균주로 사용하는 경우 주위 환경변화에 영향을 적게 받고 잡균에 의한 품질변화가 적다는 장점이 있다.The microorganism of the genus Saccharomyces is cream tan, and the microorganism of the genus Issatchenkia is cream white. Both microorganisms are a type of diffuser yeast that breed by germination and are resistant to heat and predominate when fermentation is above a certain temperature during fermentation process. It has the advantage of receiving less and changing quality due to various germs.
상기 발효는 사카로마이세스(Saccharomyces)속을 사용할 경우, 25 내지 35℃의 온도에서 24 내지 72 시간 동안 배양하는 것이 바람직하며, 이사첸키아(Issatchenkia)속을 사용할 경우, 35 내지 45℃의 온도에서 40 내지 52 시간 동안 배양하는 것이 바람직하다.The fermentation is preferably incubated for 24 to 72 hours at a temperature of 25 to 35 ℃ when using the Saccharomyces genus, 35 to 45 ℃ when using the genus Issatchenkia Incubation for 40 to 52 hours is preferred.
본 발명에서 미배아 복합발효추출액은 미배아 1 내지 10 중량%, 쌀겨 1 내지 10 중량%, 콩류 유래 펩타이드 0.1 내지 5 중량%, 피틴산 0.1 내지 5 중량%, 이인산나트륨 0.5 내지 5 중량%, 이인산칼륨 0.05 내지 2 중량%, 글루코오스 0.5 내지 5 중량%, 소포제 0.001 내지 0.1 중량% 및 잔부의 물을 포함한 원료에 프로테아제를 첨가하고 교반시키는 원료 혼합 단계; 상기 원료 혼합물에 사카로마이세스(Saccharomyces)속 및 이사첸키아(Issatchenkia)속 미생물로 이루어진 군에서 선택된 하나 이상의 미생물을 접종하여 발효시키는 발효 단계; 및 상기 발효 배양물을 여과하고 농축시키는 여과 및 농축 단계를 포함하는 공정에 의해 제조될 수 있다.In the present invention, the embryo complex composite fermentation extract is 1-10% by weight of embryos, 1-10% by weight of rice bran, 0.1-5% by weight of peptides derived from legumes, 0.1-5% by weight of phytic acid, 0.5-5% by weight of sodium diphosphate, and A raw material mixing step of adding and stirring a protease to a raw material including 0.05 to 2 wt% of potassium phosphate, 0.5 to 5 wt% of glucose, 0.001 to 0.1 wt% of an antifoaming agent, and the balance of water; A fermentation step of inoculating the raw material mixture with one or more microorganisms selected from the group consisting of Saccharomyces genus and Issatchenkia genus microorganisms; And filtration and concentration steps of filtering and concentrating the fermentation culture.
상기 여과는 여과 효율을 증진시키기 위하여 발효 배양물에 물 및 탄수화물 분해효소를 첨가하여 여과하는 것이 바람직하다.The filtration is preferably filtered by adding water and carbohydrate degrading enzyme to the fermentation culture in order to enhance the filtration efficiency.
상기 탄수화물 분해효소로는 프로모자임, 셀루클라스트, 말토게나제, 비스코자임, 테르마밀, 덱스트로자임, 울트라플로 및 AMG로 이루어진 군에서 선택된 하나 이상을 사용할 수 있고, 바람직하게는 테르마밀과 비스코자임을 동일 중량 비율로 혼합하여 사용하며, 이때 발효 배양물 총 100 중량부에 대하여 탄수화물 분해효소를 0.001 내지 1 중량부로 포함하는 것이 바람직하다.The carbohydrate degrading enzyme may be one or more selected from the group consisting of promozyme, cellulose, maltogenase, biscozyme, thermamil, dextrozzyme, ultraflo and AMG, preferably thermamil and bisco Zyme is used by mixing in the same weight ratio, and it is preferable to include carbohydrate degrading enzyme in 0.001 to 1 parts by weight based on 100 parts by weight of the fermentation culture.
상기 프로테아제는 원료 100 중량부에 대하여 0.001 내지 1 중량부로 첨가하는 것이 바람직하다.The protease is preferably added in an amount of 0.001 to 1 part by weight based on 100 parts by weight of the raw material.
본 발명에서 숙취 예방 또는 해소용 조성물의 (a) 마름 추출물, (b) 인진쑥, 녹엽, 뽕잎, 여주, 칡 및 연근의 식물발효추출물 및 (c) 미배아 복합발효추출액의 중량비는 1:75 ~ 175:1 ~ 8 일 수 있으며, 예를 들어 1:125:2일 수 있다.In the present invention, the weight ratio of (a) dry extract, (b) jinjin mugwort, green leaf, mulberry leaf, Yeoju, 칡 and lotus root of plant fermentation extract and (c) ungerminated composite fermentation extract of the hangover prevention composition in the present invention is 1:75 ~ 175: 1 to 8, for example 1: 125: 2.
본 발명에서 숙취 예방 또는 해소용 조성물은 (a) 마름 추출물, (b) 인진쑥, 녹엽, 뽕잎, 여주, 칡 및 연근의 식물발효추출물 및 (c) 미배아 복합발효추출액 이외에도 숙취 예방 또는 해소에 효과가 알려져 있는 공지의 천연물 또는 이의 추출물, 또는 활성 기능 물질 등이 더 포함될 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. In the present invention, the composition for preventing or eliminating hangover is effective in preventing or eliminating hangover in addition to (a) dried fermented extracts, (b) plant fermentation extracts of green leaves, mulberry leaves, bitter gourds, silkworms and lotus roots, and (c) complex fermented extracts of embryonic embryos. Known natural products or known extracts thereof, or active functional substances may be further included. These components can be used independently or in combination.
상기 숙취 예방 또는 해소에 효과가 알려져 있는 공지의 천연물 또는 이의 추출물은 강황(울금), 헛개나무열매, 검은콩, 황금, 구기자, 효모, 냉이, 질경이, 신선초, 쑥, 미나리, 콩나물, 감잎, 갈근, 죽력, 오리나무, 감귤피, 황기, 자리, 가시오가피 또는 이들의 추출물 등일 수 있다.Known natural products or extracts thereof that are known to be effective in preventing or eliminating hangovers are turmeric, turmeric fruit, black soybeans, golden, wolfberry, yeast, wasabi, plantain, fresh vinegar, mugwort, buttercup, bean sprout, persimmon leaf, root , Bamboo, alder, citrus, astragalus, spot, prickly pear or extract thereof.
상기 숙취 예방 또는 해소에 효과가 알려져 있는 활성 기능 물질은 타우린, L-아스파라긴산, 글루타티온, 니코틴산아미드, 푸마루산, 프로폴리스, 메타오닌, 베타인 등일 수 있다.Active functional substances known to be effective in preventing or eliminating hangovers may be taurine, L-aspartic acid, glutathione, nicotinic acid amide, fumaric acid, propolis, metaonine, betaine and the like.
상기 숙취 예방 또는 해소에 효과가 알려져 있는 공지의 천연물 또는 이의 추출물 및 활성 기능 물질의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 1 내지 약 90 중량부의 범위에서 선택되는 것이 일반적이다.The ratio of the known natural products or extracts thereof and the active functional substances which are known to be effective in preventing or eliminating the hangover is not so important but is generally selected from 1 to about 90 parts by weight per 100 parts by weight of the composition of the present invention.
본 발명에서 숙취는 알코올의 다량섭취로 인한 메스꺼움, 구토, 현기증, 갈증, 무기력, 두통, 근육통 등의 증상을 나타내는 알코올성 숙취를 의미한다.Hangover in the present invention means an alcoholic hangover showing symptoms such as nausea, vomiting, dizziness, thirst, lethargy, headache, myalgia due to large intake of alcohol.
본 발명에서 예방은 본 발명에 따른 조성물의 투여로 숙취를 억제 또는 지연시키는 모든 행위를 의미한다.Prevention in the present invention means any action that inhibits or delays hangover by administration of the composition according to the present invention.
본 발명에서 해소는 본 발명에 따른 조성물의 투여로 숙취를 호전시키거나 이롭게 변경하는 모든 행위를 의미한다.Resolving in the present invention means any action that improves or advantageously changes the hangover by administration of the composition according to the present invention.
본 발명은 또한, 본 발명에 따른 (a) 마름 추출물, (b) 인진쑥, 녹엽, 뽕잎, 여주, 칡 및 연근의 식물발효추출물 및 (c) 미배아 복합발효추출액을 포함하는 숙취 예방 또는 해소용 건강기능식품을 제공한다.The present invention is also for preventing or eliminating hangovers comprising (a) dried extract, (b) jinjin mugwort, green leaf, mulberry leaf, Yeoju, 칡 and lotus root fermentation extract and (c) embryo fermentation extract according to the present invention Provide dietary supplements.
본 발명에서 건강기능식품은 2002년 건강기능식품에 관한 법률을 통하여 새롭게 정의된 인체에 대한 기능성 및 안전성이 충분하게 확립되어 식품의약품 안전청 식약청 고시 2004-12호에 규정된 건강기능 식품원료 또는 성분 인정에 관한 규정 목록집에 수재된 건강식품임을 특징으로 한다.In the present invention, the health functional food is fully established in the functional and safety for the human body newly defined through the law on health functional food in 2002, the health functional food raw materials or ingredients recognized in the Korea Food and Drug Administration Notice 2004-12 It is characterized by health foods listed in the regulation list.
상기 숙취 예방 또는 해소용 건강기능식품은 식품학적으로 허용가능한 첨가제를 더 포함할 수 있다.The health functional food for preventing or eliminating hangovers may further comprise food acceptable additives.
본 발명의 (a) 마름 추출물, (b) 인진쑥, 녹엽, 뽕잎, 여주, 칡 및 연근의 식물발효추출물 및 (c) 미배아 복합발효추출액을 첨가할 수 있는 식품으로는, 각종 식품류, 예를 들어, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있으며, 환제, 분말, 과립, 침제, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다.As foods to which (a) dried extract of the present invention, (b) plant fermentation extracts of jinjin wormwood, green leaves, mulberry leaves, bitter gourd, 칡 and lotus root, and (c) composite fermented extract of embryonic embryos, various foods, for example For example, beverages, gums, teas, vitamin complexes, dietary supplements, and the like, may be used in the form of pills, powders, granules, acupuncture tablets, capsules, or beverages.
이때, 식품 또는 음료 중의 상기 (a) 마름 추출물, (b) 인진쑥, 녹엽, 뽕잎, 여주, 칡 및 연근의 식물발효추출물 및 (c) 미배아 복합발효추출액의 양은, 일반적으로 본 발명의 건강식품식품의 경우 전체 식품 중량의 0.01 내지 95 중량%, 바람직하게는 0.1 내지 80중량%으로 포함될 수 있으며, 건강 음료 조성물의 경우 100㎖를 기준으로 0.1 내지 100g의 비율로 포함될 수 있다.At this time, the amount of the (a) dried extract, (b) jinjin mugwort, green leaf, mulberry leaf, bitter gourd, lotus root and lotus root fermentation extract and (c) micro-fermented fermentation extract in food or beverage is generally the health food of the present invention Food may be included in 0.01 to 95% by weight, preferably 0.1 to 80% by weight of the total food weight, in the case of a health beverage composition may be included in a ratio of 0.1 to 100g based on 100ml.
본 발명의 건강 음료 조성물은 지시된 비율로 필수 성분으로서 상기 (a) 마름 추출물, (b) 인진쑥, 녹엽, 뽕잎, 여주, 칡 및 연근의 식물발효추출물 및 (c) 미배아 복합발효추출액을 함유하는 것 이외에는 액체성분에는 특별한 제한점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.The health beverage composition of the present invention contains the plant fermentation extracts of (a) dried leaf extract, (b) jinjin mugwort, green leaf, mulberry leaf, bitter gourd, lotus root and lotus root as essential ingredients in the indicated ratio, and (c) the embryo fermented complex fermentation extract. There is no particular limitation on the liquid component except for the above, and it may contain various flavors or natural carbohydrates and the like as additional ingredients, like ordinary drinks.
상술한 천연 탄수화물의 예로는 모노사카라이드, 예를 들어, 포도당, 과당 등 디사카라이드, 올리고당, 예를 들어 말토스, 수크로스 등 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등)) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다.Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and other disaccharides, oligosaccharides such as maltose and sucrose polysaccharides such as dextrins and cyclodextrins. And sugar alcohols such as xylitol, sorbitol, and erythritol. As natural flavors other than those described above, natural flavors (such as tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin)) and synthetic flavors (saccharin, aspartame, etc.) have.
상기 외에 본 발명의 조성물은 여러가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 구연산과 같은 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육, 농축액을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 1 내지 약 90 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and salts thereof. Organic acids such as citric acid, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like. In addition, the compositions of the present invention may contain flesh, concentrates for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected in the range of 1 to about 90 parts by weight per 100 parts by weight of the composition of the present invention.
본 발명에 따른 조성물은 알코올 분해능력 및 아세트알데하이드 분해능력이 우수하여 숙취 예방 또는 해소에 효과적이다.The composition according to the present invention has excellent alcohol decomposing ability and acetaldehyde decomposing ability, and is effective in preventing or eliminating hangovers.
도 1은 실시예 1에 따른 혈장시료 중 에탄올 농도를 측정한 결과를 나타낸 그래프로서, x축은 유발물질(알코올) 투여 후 경과 시간(분)을 나타내고 y축은 에탄올 농도를 나타낸다.
도 2는 실시예 2에 따른 혈장시료 중 아세트알데하이드 농도를 측정한 결과를 나타낸 그래프로서, x축은 유발물질(알코올) 투여 후 경과 시간(분)을 나타내고 y축은 아세트알데하이드 농도를 나타낸다.1 is a graph showing the result of measuring the ethanol concentration in the plasma sample according to Example 1, the x-axis represents the elapsed time (minutes) after administration of the trigger (alcohol) and the y-axis represents the ethanol concentration.
Figure 2 is a graph showing the result of measuring the acetaldehyde concentration in the plasma sample according to Example 2, the x-axis shows the elapsed time (minutes) after administration of the trigger (alcohol) and the y-axis shows the acetaldehyde concentration.
이하, 하기 실시예 및 실험예에 의해 본 발명을 보다 상세하게 설명한다. 그러나, 하기 실시예는 본 발명의 범위를 제한하는 것은 아니며, 이는 본 발명의 이해를 돕기 위한 것으로 해석되어야 할 것이다.Hereinafter, the present invention will be described in more detail with reference to the following examples and experimental examples. However, the following examples are not intended to limit the scope of the present invention, which will be construed as to aid the understanding of the present invention.
제조예Manufacturing example 1. 마름 추출물의 제조 1. Preparation of Dried Extract
경동시장에서 입수한 마름 180g을 물 3L에 넣고 100℃의 추출온도에서 6시간 동안 열수 추출을 하였다. 추출물을 여과 및 농축한 후 동결건조하여 백색의 분말가루를 얻었다.180 g of dried dried ginseng from Gyeongdong Market was placed in 3 L of water and extracted with hot water for 6 hours at an extraction temperature of 100 ° C. The extract was filtered and concentrated, and then lyophilized to obtain a white powder.
제조예Manufacturing example 2. 2. 인진쑥Inosugi , 녹엽, 뽕잎, 여주, 칡 및 연근의 식물발효추출물(식물발효추출물)의 제조Preparation of Plant Fermentation Extracts (Plant Fermentation Extracts) of Green, Green Leaves, Mulberry Leaves, Yeoju, Fructus and Lotus Root
경동시장에서 입수한 인진쑥, 녹엽, 뽕잎, 여주, 칡 및 연근을 세척한 다음 물기를 빼고 60℃에서 2시간 정도 열풍건조기에서 열처리한 후 동결건조하여 분쇄하여 분말형태로 수득하였다. 동결건조 분말형태의 인진쑥 100g 및 녹엽 100g을 혼합하고 증류수 8L를 첨가하여 교반시켜 원료를 혼합하였다. Injin mugwort, green leaf, mulberry leaf, Yeoju, 칡 and lotus root obtained from Gyeongdong market were washed and then drained and heat-treated in a hot air dryer at 60 ° C. for 2 hours and then lyophilized to obtain a powder form. 100 g of phosphorus mugwort in the form of lyophilized powder and 100 g of green leaves were mixed, and 8L of distilled water was added thereto, followed by stirring to mix the raw materials.
상기 원료 혼합물에 스트렙토마이세스 써모필러스(ATCC19282), 락토바실러스 에시도필러스(KCTC3142), 사카로마이세스 세레비지애(KCTC7904), 바실러스 섭틸리스(KCTC1022)를 1:1:1:1의 중량비로 혼합한 혼합종균 1g을 접종한 다음 3개월 동안 상온에서 통기 교반(120rpm) 배양하여 1차 배양액을 제조하였다.Streptomyces thermophilus (ATCC19282), Lactobacillus essidophilus (KCTC3142), Saccharomyces cerevisiae (KCTC7904) and Bacillus subtilis (KCTC1022) were added to the raw material mixture in a 1: 1: 1: 1 ratio. 1 g of the mixed seed mixed in the weight ratio of and then incubated for 3 months at room temperature with agitation (120rpm) to prepare a primary culture.
상기 1차 배양액에 상기 동결건조 분말형태의 인진쑥 50g, 녹엽 50g, 뽕잎 100g, 여주 100g, 칡 100g 및 연근 50g을 혼합하고 증류수 4L를 투입한 다음 2개월 동안 상온에서 통기교반 배양(120rpm)하여 2차 배양액을 제조하였다.50g of the lyophilized powder, green leaf 50g, mulberry leaf 100g, Yeoju 100g, 및 100g and lotus root 50g into the primary culture solution and 4g of distilled water was added, followed by incubation at room temperature for 2 months (120rpm) 2 Primary culture was prepared.
상기 배양물을 압착하여 활성탄을 처리하고 규조토로 처리하여 여과하였다. 여과를 용이하게 하기 위하여 배양물에 5배 분량으로 가수하고 테르마밀 및 비스코자임(Novozymes, Denmark)을 1:1로 혼합하여 중량대비 0.001%를 첨가하였다. 여과한 배양액을 45℃의 수욕조 상에서 고형분 함량이 30%가 넘도록 농축하여 짙은 갈색의 액상의 인진쑥, 녹엽, 뽕잎, 여주, 칡 및 연근의 식물발효추출물을 얻었다.The culture was compressed to treat activated carbon and filtered with diatomaceous earth. In order to facilitate filtration, the cultures were hydrolyzed in 5-fold portions, and a mixture of termamyl and biscozyme (Novozymes, Denmark) in a 1: 1 ratio was added at 0.001% by weight. The filtered culture solution was concentrated to a solid content of more than 30% in a water bath at 45 ℃ to obtain a plant fermentation extract of dark brown liquid phosphorus mugwort, green leaves, mulberry leaves, Yeoju, 칡 and lotus root.
제조예Manufacturing example 3. 3. 미배아Embryonic embryo 복합발효추출액의 제조 Preparation of Complex Fermented Extract
한국등록특허 제10-1118683호의 실시예 1에 따라 미배아 복합발효추출액을 제조하였다. 구체적으로 미배아 40 g, 탈지쌀겨 30 g, 대두 펩타이드 4 g, 피틴산 5 g, 인산수소이나트륨 10 g, 인산수소이칼륨 2.5 g, 글루코오스 15 g, 소포제(GS850, (주)금강실리콘테크) 0.25 g 및 물 500 g을 포함한 배지에 프로테아제(Protamex, Novozymes, Denmark) 0.05% (w/w)를 첨가하고 교반시켜 원료를 혼합하였다. 이때, 대두 펩타이드는 분쇄기 (HM-350, Hyun Dae Household Appliances Co., Korea)로 분쇄하여 사용하였다.According to Example 1 of Korean Patent No. 10-1118683, a microembryonic complex fermentation extract was prepared. Specifically, embryos 40 g, skim rice bran 30 g, soybean peptide 4 g, phytic acid 5 g, disodium hydrogen phosphate 10 g, dipotassium hydrogen phosphate 2.5 g, glucose 15 g, antifoaming agent (GS850, Kumkang Silicon Tech Co., Ltd.) 0.25 g And 0.05% (w / w) of protease (Protamex, Novozymes, Denmark) was added to the medium containing 500 g of water, and the raw materials were mixed by stirring. At this time, the soybean peptide was used by grinding with a grinder (HM-350, Hyun Dae Household Appliances Co., Korea).
상기 배지조성을 가진 배지에 사카로마이세스 세레비지애 또는 이사첸키아 오리엔탈리스 MFST1 (660 nm에서 흡광도 2.5이상)을 1% (w/w) 접종한 다음 30℃ 또는 40℃에서 48시간 통기 교반 (120 rpm) 배양하였다.1% (w / w) of Saccharomyces cerevisiae or Isachenchia orientalis MFST1 (absorbance of 2.5 or more at 660 nm) was inoculated into the medium having the medium composition, followed by aeration and agitation at 30 ° C. or 40 ° C. for 48 hours ( 120 rpm).
상기 배양물을 압착하여 활성탄을 처리하고 규조토로 처리하여 여과하였다. 여과를 용이하게 하기 위하여 배양물에 5배의 분량으로 가수하고 테르마밀 및 비스코자임 (Novozymes, Denmark)을 1:1로 혼합하여 중량대비 0.001%를 첨가하였다. 여과한 배양액을 45℃의 수욕조 상에서 고형분 함량이 30%가 넘도록 농축하여 갈색의 액상의 미배아 복합발효추출액을 얻었다.The culture was compressed to treat activated carbon and filtered with diatomaceous earth. In order to facilitate filtration, the cultures were hydrolyzed in 5 times the amount, and mixed with Termamyl and Biscozyme (Novozymes, Denmark) in a 1: 1 ratio and added 0.001% by weight. The filtered culture was concentrated to a solid content of more than 30% in a 45 ℃ water bath to obtain a brown liquid embryo fermentation extract.
제조예Manufacturing example 4. 마름 추출물, 식물발효추출물 및 4. Dried Extract, Fermented Plant Extract and 미배아Embryonic embryo 복합발효추출액을 포함하는 조성물 Composition containing a complex fermentation extract
제조예 1에 의해 제조된 마름 추출물 400mg, 제조예 2에 의해 제조된 짙은 갈색의 액상의 식물발효추출물 50g, 및 제조예 3에 의해 제조된 미배아 복합발효추출액 0.8g을 혼합하여 조성물을 제조하였다.The composition was prepared by mixing 400 mg of dried extract prepared in Preparation Example 1, 50 g of a dark brown liquid plant fermentation extract prepared in Preparation Example 2, and 0.8 g of the embryo embryo complex fermentation extract prepared in Preparation Example 3. .
실시예Example 1. 잔류 혈중 알코올 평균 농도의 확인 1. Confirmation of average blood alcohol concentration
1. 시험물질, 양성대조물질, 음성대조물질 및 유발물질1. Test substance, positive control substance, negative control substance and causing substance
(1) 마름 추출물+식물발효추출물+미배아 복합발효추출액(1) Dried Extract + Plant Fermentation Extract + Embryonic Complex Fermentation Extract
제조예 4에 의해 제조된 마름 추출물, 식물발효추출물 및 미배아 복합발효추출액을 포함하는 조성물을 증류수 50ml에 혼합하여 총 100ml가 되게 준비하였다.The composition comprising the dry extract, plant fermentation extract and the embryo embryo complex fermentation extract prepared in Preparation Example 4 was mixed to 50ml of distilled water to prepare a total of 100ml.
(2) 마름 추출물(2) dry extract
제조예 1에 의해 제조된 백색의 분말가루 마름 추출물 400mg을 측량하여 증류수 100ml에 녹여 준비하였다.400 mg of the white powdered powder dry powder prepared in Preparation Example 1 was measured and dissolved in 100 ml of distilled water.
(3) 식물발효추출물(3) plant fermented extract
제조예 2에 의해 제조된 식물발효추출물 50g을 측량하여 증류수 50ml에 혼합하여 총 100ml가 되게 준비하였다.50 g of the plant fermentation extract prepared in Preparation Example 2 was measured and mixed with 50 ml of distilled water to prepare a total of 100 ml.
(4) 미배아 복합발효추출액(4) Microembryonic Fermentation Extract
제조예 3에 의해 제조된 미배아 복합발효추출액 1.6g을 측량하여 증류수 100ml에 녹여 준비하였다.1.6 g of the embryo fermented extract prepared in Preparation Example 3 was measured and dissolved in 100 ml of distilled water.
(5) 마름 추출물+식물발효추출물(5) Dried Extract + Plant Fermentation Extract
제조예 1에 의해 제조된 백색의 분말가루 마름 추출물 400mg, 제조예 2에 의해 제조된 식물발효추출물 50g을 측량하여 증류수 50ml에 혼합하여 총 100ml가 되게 준비하였다.White powder powder dry powder 400mg prepared by Preparation Example 1, 50g of the plant fermentation extract prepared by Preparation Example 2 was measured and mixed in 50ml of distilled water to prepare a total of 100ml.
(6) 마름 추출물+미배아 복합발효추출액(6) Dried Extract + Embryonic Complex Fermentation Extract
제조예 1에 의해 제조된 백색의 분말가루 마름 추출물 400mg, 제조예 3에 의해 제조된 미배아 복합발효추출액 0.8g을 측량하여 증류수 100ml에 녹여 준비하였다.400 mg of the white powdered powder dried powder prepared in Preparation Example 1, 0.8 g of the microembryonic complex fermentation extract prepared in Preparation Example 3 were measured, and dissolved in 100 ml of distilled water.
(7) 식물발효추출물+미배아 복합발효추출액(7) Plant Fermented Extract + Embryonic Complex Fermented Extract
제조예 2에 의해 제조된 식물발효추출물 50g, 제조예 3에 의해 제조된 미배아 복합발효추출액 0.8g을 측량하여 증류수 50ml에 혼합하여 총 100ml가 되게 준비하였다.50 g of the plant fermentation extract prepared in Preparation Example 2, 0.8 g of the embryo embryo complex fermentation extract prepared in Preparation Example 3 were measured and mixed with 50 ml of distilled water to prepare a total of 100 ml.
(8) 양성대조물질 및 음성대조물질(8) positive control and negative control
양성대조물질로는 시판 중인 여명 808((주) 그래미, 한국)을 이용(양성대조군)하였고, 음성대조물질로는 물을 이용(음성대조군)하였다.As a positive control, commercially available Dawn 808 (Grammy, Korea) was used (positive control) and water was used as a negative control (negative control).
(9) 유발물질(9) causing substances
40% 알코올(J.T. Baker, USA)을 이용하였다.40% alcohol (J.T. Baker, USA) was used.
2. 시험기기2. Test equipment
마이크로플레이트 리더(Spectra Max M2, Molecular Device, Sunnyvale, CA, USA), 10, 100, 200 및 1,000㎕ 용량 파이페트((Eppendorf, Germany), 원심분리기(Union 5KR, 한일, 한국), 볼텍스 믹서(VM-3000, TALBOYS, USA)를 이용하였다.Microplate Reader (Spectra Max M2, Molecular Device, Sunnyvale, CA, USA), 10, 100, 200 and 1,000 μl pipettes (Eppendorf, Germany), Centrifuge (Union 5KR, Hanil, Korea), Vortex Mixer ( VM-3000, TALBOYS, USA).
3. 시험동물(3. Test animal 비임상Nonclinical 시험계Test system ))
(1) 실험동물(1) Experimental animals
한림실험동물에서 입수한 Sprague Dawley Rat를 이용하였다. 입수 시 주령 및 체중범위는 수컷 7주령 및 200 내지 220g이었다.Sprague Dawley Rat obtained from Hallim experimental animals was used. Age and body weight range from 7 weeks of age and 200-220 g of male.
(2) 순환기간(2) Cycle period
상기 실험동물은 입수 후 7일간 순화 후 시험에 공여하였다.The experimental animals were donated to the test after purification for 7 days after acquisition.
(3) 사육조건(3) Breeding conditions
사육조건은 온도 23±3℃, 상대습도 55±15%, 환기횟수 10∼20회/시간, 조명시간 12시간 (오전 8시 점등∼오후 8시 소등)의 조건인 랫트 동물실에서 사육하였으며 동물은 적량의 깔개를 담은 폴리카보네이트 사육상자 (W 235 x L 380 x H 175 mm)에서 검역 및 순화기간에는 3 마리/사육상자 이하로 사육하였다. 실험에 공급된 사료는 방사선 조사로 멸균된 실험동물용 고형사료를 한림실험동물로부터 공급받아 자유롭게 섭취하도록 하였다.Breeding conditions were raised in the rat animal room under the conditions of temperature 23 ± 3 ℃, relative humidity 55 ± 15%, ventilation frequency 10-20 times / hour, lighting time 12 hours (lighting at 8 am to 8 pm). The polycarbonate cages (W 235 x L 380 x H 175 mm) containing silver rugs were raised to less than 3 animals / cage during quarantine and purifying periods. Feed fed to the experiment was to receive a solid feed for experimental animals sterilized by irradiation irradiated from Hallim experimental animals freely ingested.
4. 시험물질의 투여4. Administration of Test Substance
시험물질, 양성대조물질 및 음성대조물질은 유발물질(알코올) 투여 전 전처리 방식으로 수행하였다. 시험물질, 양성대조물질 및 음성대조물질을 투여하고 30분 후 유발물질을 투여하였다.Test substance, positive control substance and negative control substance were performed by pretreatment before administration of the trigger (alcohol). Test substance, positive control and negative control were administered 30 minutes after the administration of the trigger.
시험물질, 양성대조물질, 음성대조물질 및 유발물질(알코올)의 투여경로는 임상경로인 경구로 진행하였다. 경구투여는 한 손으로 시험동물의 경배부를 잡아 고정하고 다른 한손으로 경구용 스테인레스 존데를 이용하여 위 내에 직접 투여하였다. 투여액량은 시험물질 및 음성대조물질은 1.7 mL/kg, 양성대조물질은 2.5 mL/kg으로 유발물질인 40% 알코올은 8.4 mL/kg 투여액량을 산출하여 투여하였다. 투여횟수는 절식 시험군의 경우 투여 전 8시간 이상을 절식하였으며 시험군 모두 오전 9시에 시작하여 11시 이전에 투여를 종료하였다. The administration route of test substance, positive control substance, negative control substance and inducing substance (alcohol) was proceeded orally. Oral administration was performed by grasping and fixing the cervical part of the test animal with one hand and directly using the oral stainless sonde with the other hand in the stomach. The dose was 1.7 mL / kg for test substance and negative control, 2.5 mL / kg for positive control and 8.4 mL / kg for 40% alcohol. In the fasting test group, the frequency of fasting was fasted at least 8 hours before the administration.
시험물질, 대조물질 투여는 하기 표 1과 같았다.Test substance and control substance administration were as shown in Table 1 below.
[표 1][Table 1]
5. 생체시료 분석5. Biological Sample Analysis
(1) 생체시료(혈장시료)의 채취(1) Collection of biological samples (plasma samples)
채혈은 시험물질 투여개시일에 실시하였다. 채혈 시간은 시험물질, 양성대조물질, 음성대조물질을 투여하고 30분 후 40% 알코올 투여하고, 40% 알코올 투여 후 30, 150, 270, 390분에 채혈하였다. 채혈은 경정맥에서 약 800 ㎕씩 채혈하고, 4,000 rpm으로 약 10 분간 원심분리한 후 상층 (혈장)을 분리하였다. 분리한 혈장은 분석 전까지 - 70℃로 설정되어 있는 deep freezer에 보관하였다.Blood collection was performed at the start of administration of the test substance. The blood collection time was 30% after administration of the test substance, positive control and negative control, 40% alcohol, 30, 150, 270, 390 minutes after 40% alcohol administration. About 800 μl of blood was collected from the jugular vein, centrifuged at 4,000 rpm for about 10 minutes, and the upper layer (plasma) was separated. The separated plasma was stored in a deep freezer set at −70 ° C. until analysis.
(2) 알코올 농도의 측정 및 결과(2) Measurement and result of alcohol concentration
알코올에 대한 혈장시료의 농도분석은 키트(r-biopharm, Roche)를 이용하였고, 상기 키트의 제조사의 지시에 따른 전처리 방법에 따라 처리 후 마이크로플레이트 리더(Spectra Max M2, Molecular Device, Sunnyvale, CA, USA)를 이용하여 측정하였다.Plasma sample concentration analysis for alcohol was performed using a kit (r-biopharm, Roche), and the microplate reader (Spectra Max M2, Molecular Device, Sunnyvale, CA,) after treatment according to the pretreatment method according to the manufacturer's instructions. USA).
반응 혼합물 3ml(potassium phosphate buffer pH 9 + NAD tablet)에 혈장시료 100㎕를 혼합하였다. 3분 동안 20℃에서 배양한 후, 340nm에서 흡광도를 측정하였다(A1). 이 혼합액에 ADH(alcohol dehydrogenase)를 50㎕ 넣고 5분 동안 20℃에서 배양한 후, 340nm에서 흡광도를 측정하였다(A2).100 μl of the plasma sample was mixed into 3 ml of the reaction mixture (potassium phosphate buffer pH 9 + NAD tablet). After incubation at 20 ° C. for 3 minutes, the absorbance at 340 nm was measured (A1). 50 μl of ADH (alcohol dehydrogenase) was added to the mixed solution, incubated at 20 ° C. for 5 minutes, and the absorbance was measured at 340 nm (A2).
알코올 농도 = 0.7256/6.3*AAlcohol Concentration = 0.7256 / 6.3 * A
A (혈중내 변화된 측정값) = sample (A2-A1)- blank (A2-A1)A (measured change in blood) = sample (A2-A1)-blank (A2-A1)
상기 혈장시료 중 에탄올 농도를 측정한 결과의 평균값을 표 2와 도 1에 나타내었다.The average value of the result of measuring the ethanol concentration in the plasma sample is shown in Table 2 and FIG.
모든 채혈 시간대에서 마름 추출물+식물발효추출물+미배아 복합발효추출액 군은 마름 추출물 군, 식물발효추출물 군, 미배아 복합발효추출액 군, 마름 추출물+식물발효추출물 군, 마름 추출물+미배아 복합발효추출액 군, 식물발효추출물+미배아 복합발효추출액 군은 물론 양성대조물질 군인 여명 808 보다 혈중 내의 에탄올의 농도가 낮음을 확인할 수 있었다. 특히 도 1에서 나타난 바와 같이 마름 추출물+식물발효추출물+미배아 복합발효추출액 군은 150분대 이후 에탄올 농도 감소 폭이 현저함을 확인할 수 있었다. 또한 최종 채혈 시간대인 390분대에 마름 추출물+식물발효추출물+미배아 복합발효추출액 군은 다른 모든 군 보다 혈중 내의 알코올의 농도를 유의적으로 감소되는 것을 확인할 수 있었다. 따라서, 상기 마름 추출물+식물발효추출물+미배아 복합발효추출액 군의 조성물은 다른 모든 군의 조성물보다 알코올 분해능력이 현저하게 우수함을 확인할 수 있었다.At all blood collection periods, the dry extract + plant fermentation extract + embryo germ extract fermentation group were the extracts of the dry extract group, the plant fermentation extract group, the embryo embryo extract fermentation extract group, the dry extract + plant fermentation extract group, the dry extract + embryo fermentation complex fermentation extract It was confirmed that the concentration of ethanol in the blood was lower than that of the group, plant fermentation extract + embryo fermentation complex fermentation extract group, as well as the positive control soldier Dawn 808. In particular, as shown in FIG. 1, the dry extract + plant fermentation extract + embryo embryo fermentation extract group showed a significant decrease in ethanol concentration after 150 minutes. In addition, it was confirmed that the concentration of alcohol in the blood was significantly reduced in the dry extract + plant fermentation extract + embryo embryo fermentation extract group at 390 minutes, the final blood collection time. Therefore, the composition of the dried extract + plant fermentation extract + embryo embryo complex fermentation extract group was confirmed that the alcohol decomposition ability is significantly superior to the composition of all other groups.
[표 2][Table 2]
실시예Example 2. 잔류 혈중 아세트알데히드 평균 농도의 확인 2. Identification of Acetaldehyde Average Concentration in Residual Blood
실시예 1. 잔류 혈중 알코올 평균 농도의 확인에서 5. 생체시료 분석의 (2) 알코올 농도의 측정 및 결과를 제외한 조건을 동일하게 처리하여 잔류혈중 아세트알데하이드 평균 농도를 측정하였다.Example 1 In Confirmation of Average Residual Blood Alcohol Concentration 5. Means of Acetaldehyde in Residual Blood were measured by the same treatment except for the measurement and results of (2) Alcohol concentration in the biological sample analysis.
아세트알데하이드에 대한 혈장시료의 농도분석은 키트(Megazyme, 엠알텍)를 이용하였고, 상기 키트의 제조사의 지시에 따른 전처리 방법에 따라 처리 후 마이크로플레이트 리더(Spectra Max M2, Molecular Device, Sunnyvale, CA, USA)를 이용하여 측정하였다.Analysis of the concentration of plasma samples for acetaldehyde using a kit (Megazyme, MALTECH), after the treatment according to the pretreatment method according to the manufacturer's instructions of the kit microplate reader (Spectra Max M2, Molecular Device, Sunnyvale, CA, USA).
증류수 2ml을 혈장시료 200㎕에 혼합하였다. 이에 반응 혼합물(potassium phosphate buffer pH 9)를 첨가하였다. 이에 NAD 200㎕를 첨가하고 3분 동안 20℃에서 배양한 후, 340nm에서 흡광도를 측정하였다(A1). 이 혼합액에 ALDH(acetaldehyde dehydrogenase)를 50㎕ 넣고 5분 동안 20℃에서 배양한 후, 340nm에서 흡광도를 측정하였다(A2).2 ml of distilled water was mixed into 200 µl of the plasma sample. To this was added a reaction mixture (potassium phosphate buffer pH 9). 200 µl of the NAD was added thereto and incubated at 20 ° C. for 3 minutes, and then absorbance was measured at 340 nm (A1). 50 μl of ALDH (acetaldehyde dehydrogenase) was added to the mixed solution, and incubated at 20 ° C. for 5 minutes, and the absorbance was measured at 340 nm (A2).
아세트알데하이드 농도 = 116.7325/630*AAcetaldehyde concentration = 116.7325 / 630 * A
A (혈중내 변화된 측정값) = sample (A2-A1)- blank (A2-A1)A (measured change in blood) = sample (A2-A1)-blank (A2-A1)
상기 혈장시료 중 아세트알데하이드 농도를 측정한 결과의 평균값을 표 3과 도 2에 나타내었다.The average value of the result of measuring the acetaldehyde concentration in the plasma sample is shown in Table 3 and FIG.
채혈 시간대인 150분대, 270분대, 390분대에서 마름 추출물+식물발효추출물+미배아 복합발효추출액 군은 마름 추출물 군, 식물발효추출물 군, 미배아 복합발효추출액 군, 마름 추출물+식물발효추출물 군, 마름 추출물+미배아 복합발효추출액 군, 식물발효추출물+미배아 복합발효추출액 군은 물론 양성대조물질 군인 여명 808 보다 혈중 내의 아세트알데하이드의 농도가 낮음을 확인할 수 있었다. 또한, 도 2에서 나타난 바와 같이 마름 추출물+식물발효추출물+미배아 복합발효추출액 군은 150분대 이후 아세트알데하이드 농도의 변동폭이 작으면서 낮게 유지됨을 확인할 수 있었다.At the time of blood collection, 150 minutes, 270 components, 390 components, the dry extract + plant fermentation extract + embryo embryo fermentation extract group was the dry extract group, plant fermentation extract group, embryo embryo fermentation extract group, dried extract + plant fermentation extract group, It was confirmed that the concentration of acetaldehyde in the blood was lower than the dry extract + embryo embryo fermentation extract group, the plant ferment extract extract + embryo embryo complex fermentation extract group, as well as the positive control soldier Dawn 808. In addition, as shown in FIG. 2, the dry extract + plant fermentation extract + embryo embryo fermentation extract group was confirmed to remain low while the fluctuation range of acetaldehyde concentration after 150 minutes.
도 1에서 살펴본 바와 같이, 마름 추출물+식물발효추출물+미배아 복합발효추출액 군은 150분대 이후 알코올 농도가 현저하게 감소하여 알코올 대사로 인한 아세트알데하이드 생성이 다른 모든 군에 비해 현저히 많았을 것임에도 불구하고 다른 모든 군에 비해 낮은 아세트알데하이드 농도를 나타낸다는 것은 상기 마름 추출물+식물발효추출물+미배아 복합발효추출액 군의 조성물이 다른 모든 군의 조성물보다 아세트알데하이드 분해능력이 현저하게 우수하다는 것을 의미한다.As shown in FIG. 1, the dry extract + plant fermentation extract + embryo embryo fermentation extract group significantly reduced alcohol concentration after 150 minutes, despite the fact that acetaldehyde production due to alcohol metabolism was significantly higher than in all other groups. And lower acetaldehyde concentration than all other groups means that the composition of the dry extract + plant fermentation extract + embryo embryo fermentation extract group is significantly superior to the composition of acetaldehyde than all the other compositions.
[표 3] [Table 3]
상기 실시예 1 및 2의 결과는 마름 추출물+식물발효추출물+미배아 복합발효추출액 군의 조성물이 다른 군의 조성물보다 빠르게 알코올 분해능력 및 아세트알데하이드 분해능력이 우수하여 단시간에 알코올성 숙취를 해소할 수 있음을 보여준다.The results of Examples 1 and 2 is that the composition of the dry extract + plant fermentation extract + embryo embryo complex fermentation extract group has better alcohol decomposing ability and acetaldehyde decomposing ability than the other group composition to resolve the alcoholic hangover in a short time Shows that there is.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120077421A KR101247927B1 (en) | 2012-07-16 | 2012-07-16 | Composition for prevention or relief of alcoholic hangover |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120077421A KR101247927B1 (en) | 2012-07-16 | 2012-07-16 | Composition for prevention or relief of alcoholic hangover |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101247927B1 true KR101247927B1 (en) | 2013-03-26 |
Family
ID=48182625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120077421A KR101247927B1 (en) | 2012-07-16 | 2012-07-16 | Composition for prevention or relief of alcoholic hangover |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101247927B1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101525478B1 (en) * | 2013-09-06 | 2015-06-03 | 한미약품 주식회사 | Food composition for relieving hangover |
KR101615199B1 (en) * | 2014-02-20 | 2016-04-25 | 동아대학교 산학협력단 | Functional compositions for relieving hangovers and protecting a liver, healthy food and food additive comprising the same |
CN105580899A (en) * | 2014-11-15 | 2016-05-18 | 柳易程 | Alcoholism-relieving traditional Chinese medicine yogurt and preparation method thereof |
KR101827326B1 (en) * | 2016-02-04 | 2018-02-09 | 문수영 | Chinese medical composition for curing a hangover |
WO2019017603A3 (en) * | 2017-07-20 | 2019-03-07 | 주식회사 네츄럴 라이프 | Composition for improving hangovers containing trapa japonica flerow extract and curcumin as active ingredient |
KR20190125735A (en) * | 2018-04-30 | 2019-11-07 | 동아제약 주식회사 | Composition for hepatoprotective activity comprising Turmeric extract solution and Rice Soybean extract |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060011914A (en) * | 2006-01-19 | 2006-02-03 | (주)케어메딕스 | Composition and methods for the manufacturing the functional food on preventing and releasing from alcoholic hangover |
KR20100077678A (en) * | 2008-12-29 | 2010-07-08 | 주식회사 진로 | Composition for alleviating a hangover comprising an extract of trapa japonica flerov |
KR101118683B1 (en) * | 2010-10-14 | 2012-03-13 | 농업회사법인주식회사 네이처팜 | Fermented product comprising rice germ, rice bran and soybean peptide fermented by saccaromyces or issatchenkia to give alcohol tolerance and preparation method thereof |
-
2012
- 2012-07-16 KR KR1020120077421A patent/KR101247927B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060011914A (en) * | 2006-01-19 | 2006-02-03 | (주)케어메딕스 | Composition and methods for the manufacturing the functional food on preventing and releasing from alcoholic hangover |
KR20100077678A (en) * | 2008-12-29 | 2010-07-08 | 주식회사 진로 | Composition for alleviating a hangover comprising an extract of trapa japonica flerov |
KR101118683B1 (en) * | 2010-10-14 | 2012-03-13 | 농업회사법인주식회사 네이처팜 | Fermented product comprising rice germ, rice bran and soybean peptide fermented by saccaromyces or issatchenkia to give alcohol tolerance and preparation method thereof |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101525478B1 (en) * | 2013-09-06 | 2015-06-03 | 한미약품 주식회사 | Food composition for relieving hangover |
KR101615199B1 (en) * | 2014-02-20 | 2016-04-25 | 동아대학교 산학협력단 | Functional compositions for relieving hangovers and protecting a liver, healthy food and food additive comprising the same |
CN105580899A (en) * | 2014-11-15 | 2016-05-18 | 柳易程 | Alcoholism-relieving traditional Chinese medicine yogurt and preparation method thereof |
KR101827326B1 (en) * | 2016-02-04 | 2018-02-09 | 문수영 | Chinese medical composition for curing a hangover |
WO2019017603A3 (en) * | 2017-07-20 | 2019-03-07 | 주식회사 네츄럴 라이프 | Composition for improving hangovers containing trapa japonica flerow extract and curcumin as active ingredient |
KR20190125735A (en) * | 2018-04-30 | 2019-11-07 | 동아제약 주식회사 | Composition for hepatoprotective activity comprising Turmeric extract solution and Rice Soybean extract |
WO2019212202A1 (en) * | 2018-04-30 | 2019-11-07 | 동아제약 주식회사 | Composition for liver protection comprising turmeric extract and rice germ soybean fermented extract |
KR102648340B1 (en) * | 2018-04-30 | 2024-03-18 | 동아제약 주식회사 | Composition for hepatoprotective activity comprising Turmeric extract solution and Rice Soybean extract |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101247927B1 (en) | Composition for prevention or relief of alcoholic hangover | |
KR101671909B1 (en) | Method for producing CHESTNUT INNER SKIN fermented beverage and CHESTNUT INNER SKIN fermented beverage produced by the same | |
JP4616413B1 (en) | Fermented food manufacturing method and fermented food | |
KR101799424B1 (en) | Astragalus membranaceus Fermentation product and its manufacturing method | |
KR20120123860A (en) | Composition for relieving hangover or improving liver function | |
CN107691704A (en) | A kind of black-tea fungus drink and preparation method thereof | |
KR20220013451A (en) | Fermented Noni Vinegar Comprising Lactic Acid Bacteria Fermented Noni and Coconut Sugar and Method for Preparing Lactic Acid Bacteria Fermented Noni | |
KR101909423B1 (en) | Manufacturing method of low salinity toenjang | |
KR101198914B1 (en) | Fermented Burdock having anti-cavity funciton | |
KR101122586B1 (en) | Hang over beverage containing freeze-dring Abalone flesh and It's manufacturing method | |
KR101448138B1 (en) | Beverage comprising extract of mulberry leaves and herbs | |
KR20170065452A (en) | Lotus tea beverage and manufacturing method thereof | |
KR101307202B1 (en) | Cultured root of mountain ginseng crmg 5 with improved content of ppt type saponin and method of producing the same | |
CN109349483A (en) | A kind of plant energy functional beverage production method | |
KR20160060834A (en) | Compositions for culture media of Kefir grain comprising plant extract and compositions for improving skin conditions comprising fermented products using the same | |
CN108578589B (en) | Composite effervescent tablet for relieving alcoholism and preparation method thereof | |
KR100536083B1 (en) | Mixture of pine tree leaves supernatant juice fermentation solution and Lespedeza cuneate G. Don extract and health food containing the same | |
KR102082820B1 (en) | Fermented vinegar beverage concentrates and manufacturing method thereof | |
KR101203790B1 (en) | Method for manufacturing soybean paste including butterbur and soybean paste thereof | |
CN105639458A (en) | Preparation method of probiotics-containing barley seedling xylitol nutritional powder | |
KR101909936B1 (en) | Food composition for enhancing function of immunity comprising fermented extract from material natural food by lactic acid bacteria and preparation method thereof | |
CN104531444A (en) | Gingko fruit wine and preparation method thereof | |
KR101523525B1 (en) | A Manufacturing methods of grinded Allium senescens drink fermented by Lactic Acid Bacteria | |
KR20200039941A (en) | Noni Powder Comprising Fermentated and Aged Noni Fruit and Method for Preparing the Same | |
KR102593227B1 (en) | A Diet Drink for Anti-Obesity Using Buckwheat Sprouts and Production method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20160104 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20161212 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20171212 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20181218 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20191212 Year of fee payment: 8 |